GRI · Annual Report (Form 10-K) · Filed January 30, 2026

Gri Bio Inc — 10-K exhibit

gri-202510k_ex232.htm

Document

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

GRI Bio, Inc.

La Jolla, CA

We consent to the inclusion in the Registration Statements on Form S-1 (Nos. 333-274972, 333-276205, 333-280323, 333-286072 and 333-291999), Form S-3 (Nos. 333-279348, 333-283234,333-272276, 333274972 and 333-293065), and Form S-8 (Nos. 333-284149, 333-289593, 333-255972 and 333-293063) of GRI Bio, Inc. (“the Company”), of our report dated March 14, 2025, on our audits of the consolidated financial statements of GRI Bio, Inc. as of December 31, 2024, for the year then ended, which report is included in this Annual Report on Form 10-K to be filed on or about January 29, 2026. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern.

/s/ Sadler, Gibb & Associates, LLC

Sadler, Gibb & Associates, LLC

Draper, UT

January 29, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer